These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
174 related articles for article (PubMed ID: 34020022)
21. Prediction of anti-CD25 and 5-FU treatments efficacy for pancreatic cancer using a mathematical model. Shafiekhani S; Dehghanbanadaki H; Fatemi AS; Rahbar S; Hadjati J; Jafari AH BMC Cancer; 2021 Nov; 21(1):1226. PubMed ID: 34781899 [TBL] [Abstract][Full Text] [Related]
22. Tumor Cell-Intrinsic USP22 Suppresses Antitumor Immunity in Pancreatic Cancer. Li J; Yuan S; Norgard RJ; Yan F; Yamazoe T; Blanco A; Stanger BZ Cancer Immunol Res; 2020 Mar; 8(3):282-291. PubMed ID: 31871120 [TBL] [Abstract][Full Text] [Related]
23. Micellar nanoparticles inhibit breast cancer and pulmonary metastasis by modulating the recruitment and depletion of myeloid-derived suppressor cells. Lu Z; Liu H; Ma L; Ren K; He Z; Li M; He Q Nanoscale; 2022 Dec; 14(46):17315-17330. PubMed ID: 36374496 [TBL] [Abstract][Full Text] [Related]
24. Neoadjuvant Therapy Remodels the Pancreatic Cancer Microenvironment via Depletion of Protumorigenic Immune Cells. Mota Reyes C; Teller S; Muckenhuber A; Konukiewitz B; Safak O; Weichert W; Friess H; Ceyhan GO; Demir IE Clin Cancer Res; 2020 Jan; 26(1):220-231. PubMed ID: 31585935 [TBL] [Abstract][Full Text] [Related]
25. Myeloid-derived suppressor cells: Bridging the gap between inflammation and pancreatic adenocarcinoma. Sharma V; Aggarwal A; Jacob J; Sahni D Scand J Immunol; 2021 May; 93(5):e13021. PubMed ID: 33455004 [TBL] [Abstract][Full Text] [Related]
26. Drug-Loaded Mesoporous Silica Nanoparticles Enhance Antitumor Immunotherapy by Regulating MDSCs. Xu C; Amna N; Shi Y; Sun R; Weng C; Chen J; Dai H; Wang C Molecules; 2024 May; 29(11):. PubMed ID: 38893313 [TBL] [Abstract][Full Text] [Related]
28. Yes-associated protein mediates immune reprogramming in pancreatic ductal adenocarcinoma. Murakami S; Shahbazian D; Surana R; Zhang W; Chen H; Graham GT; White SM; Weiner LM; Yi C Oncogene; 2017 Mar; 36(9):1232-1244. PubMed ID: 27546622 [TBL] [Abstract][Full Text] [Related]
29. Chemotherapy priming of the Pancreatic Tumor Microenvironment Promotes Delivery and Anti-Metastasis Efficacy of Intravenous Low-Molecular-Weight Heparin-Coated Lipid-siRNA Complex. Yu Q; Qiu Y; Chen X; Wang X; Mei L; Wu H; Liu K; Liu Y; Li M; Zhang Z; He Q Theranostics; 2019; 9(2):355-368. PubMed ID: 30809279 [TBL] [Abstract][Full Text] [Related]
30. Facile one-pot formulation of TRAIL-embedded paclitaxel-bound albumin nanoparticles for the treatment of pancreatic cancer. Min SY; Byeon HJ; Lee C; Seo J; Lee ES; Shin BS; Choi HG; Lee KC; Youn YS Int J Pharm; 2015 Oct; 494(1):506-15. PubMed ID: 26315118 [TBL] [Abstract][Full Text] [Related]
31. The New Era of Cancer Immunotherapy: Targeting Myeloid-Derived Suppressor Cells to Overcome Immune Evasion. De Cicco P; Ercolano G; Ianaro A Front Immunol; 2020; 11():1680. PubMed ID: 32849585 [TBL] [Abstract][Full Text] [Related]
32. Tumor-Derived Myeloid Cell Chemoattractants and T Cell Exclusion in Pancreatic Cancer. Vonderheide RH; Bear AS Front Immunol; 2020; 11():605619. PubMed ID: 33304355 [TBL] [Abstract][Full Text] [Related]
33. Biomimetic nanoparticles delivered hedgehog pathway inhibitor to modify tumour microenvironment and improved chemotherapy for pancreatic carcinoma. Jiang T; Zhang B; Zhang L; Wu X; Li H; Shen S; Luo Z; Liu X; Hu Y; Pang Z; Jiang X Artif Cells Nanomed Biotechnol; 2018; 46(sup1):1088-1101. PubMed ID: 29484905 [TBL] [Abstract][Full Text] [Related]
34. Repression of MUC1 Promotes Expansion and Suppressive Function of Myeloid-Derived Suppressor Cells in Pancreatic and Breast Cancer Murine Models. Sahraei M; Bose M; Sanders JA; De C; DasRoy L; Nath S; Brouwer CR; Mukherjee P Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34070449 [TBL] [Abstract][Full Text] [Related]
35. Current advances and outlooks in immunotherapy for pancreatic ductal adenocarcinoma. Fan JQ; Wang MF; Chen HL; Shang D; Das JK; Song J Mol Cancer; 2020 Feb; 19(1):32. PubMed ID: 32061257 [TBL] [Abstract][Full Text] [Related]
36. Targeting the crosstalk between cytokine-induced killer cells and myeloid-derived suppressor cells in hepatocellular carcinoma. Yu SJ; Ma C; Heinrich B; Brown ZJ; Sandhu M; Zhang Q; Fu Q; Agdashian D; Rosato U; Korangy F; Greten TF J Hepatol; 2019 Mar; 70(3):449-457. PubMed ID: 30414862 [TBL] [Abstract][Full Text] [Related]
37. The Emerging Role of Myeloid-Derived Suppressor Cells in the Glioma Immune Suppressive Microenvironment. Mi Y; Guo N; Luan J; Cheng J; Hu Z; Jiang P; Jin W; Gao X Front Immunol; 2020; 11():737. PubMed ID: 32391020 [TBL] [Abstract][Full Text] [Related]
38. Enhanced Melanoma-Targeted Therapy by "Fru-Blocked" Phenyboronic Acid-Modified Multiphase Antimetastatic Micellar Nanoparticles. Long Y; Lu Z; Mei L; Li M; Ren K; Wang X; Tang J; Zhang Z; He Q Adv Sci (Weinh); 2018 Nov; 5(11):1800229. PubMed ID: 30479911 [TBL] [Abstract][Full Text] [Related]
39. Local and systemic immunosuppression in pancreatic cancer: Targeting the stalwarts in tumor's arsenal. Mundry CS; Eberle KC; Singh PK; Hollingsworth MA; Mehla K Biochim Biophys Acta Rev Cancer; 2020 Aug; 1874(1):188387. PubMed ID: 32579889 [TBL] [Abstract][Full Text] [Related]
40. Impact of Surgery-Induced Myeloid-derived Suppressor Cells and the NOX2/ROS Axis on Postoperative Survival in Human Pancreatic Cancer. Grauers Wiktorin H; Aydin E; Kiffin R; Vilhav C; Bourghardt Fagman J; Kaya M; Paul S; Westman B; Bratlie SO; Naredi P; Hellstrand K; Martner A Cancer Res Commun; 2024 Apr; 4(4):1135-1149. PubMed ID: 38598844 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]